systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-742Research ArticleСТАТЬИARTICLESРоль силденафила в лечении больных легочной артериальной гипертензиейМартынюкТ. В.noemail@neicon.ruЧазоваИ. Е.noemail@neicon.ruИнститут клинической кардиологии им. А.Л.Мясникова ФГБУ РКНПК Минздрава РФRussian Federation201209022023922329Copyright © Мартынюк Т.В., Чазова И.Е., 20232023Мартынюк Т.В., Чазова И.Е.Мартынюк Т.В., Чазова И.Е.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/742ReferencesРоссийские рекомендации по диагностике и лечению легочной гипертензии. ВНОК, 2007.Российские рекомендации по диагностике и лечению легочной гипертензии. ВНОК, 2007.Чазова И.Е., Наконечников С.Н., Мартынюк T.B. Новые возможности в лечении больных легочной артериальной гипертензией: Европейские рекомендации 2009 г. Кардиоваскулярная терапия и профилактика. 2010; 2: 86-99.Чазова И.Е., Наконечников С.Н., Мартынюк T.B. Новые возможности в лечении больных легочной артериальной гипертензией: Европейские рекомендации 2009 г. Кардиоваскулярная терапия и профилактика. 2010; 2: 86-99.Guidelines for the diagnosis and treatment of pulmonary hypertension. The task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-537.Guidelines for the diagnosis and treatment of pulmonary hypertension. The task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-537.Pfizer Inc. FDA Approves Pfizer's Revatio as treatment for pulmonary arterial hypertension. http://www.pfizer.com/pfizer/are/news_releases_2005Pfizer Inc. FDA Approves Pfizer's Revatio as treatment for pulmonary arterial hypertension. http://www.pfizer.com/pfizer/are/news_releases_2005Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in pulmonary hypertension. N Engl J Med 2000; 343: 1342.Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in pulmonary hypertension. N Engl J Med 2000; 343: 1342.Chockalingam A, Gnanavelu G, Venkatesan S et al. Efficacy and optimal dose of sildenafil in primary pulmonary hypertension. Int J Cardiol 2005; 99 (1): 91-5.Chockalingam A, Gnanavelu G, Venkatesan S et al. Efficacy and optimal dose of sildenafil in primary pulmonary hypertension. Int J Cardiol 2005; 99 (1): 91-5.Lee AJ, Chiao TB, Tsang MP. Sildenafil for pulmonary hypertension. Ann Pharmacother 2005; 39 (5): 869-84.Lee AJ, Chiao TB, Tsang MP. Sildenafil for pulmonary hypertension. Ann Pharmacother 2005; 39 (5): 869-84.Mehta S. Sildenafil for pulmonary arterial hypertension: exciting, but protection required. Chest 2003; 123 (4): 989-92.Mehta S. Sildenafil for pulmonary arterial hypertension: exciting, but protection required. Chest 2003; 123 (4): 989-92.Michelakis ED, Tymchak W, Noga M et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003; 108: 2066-9.Michelakis ED, Tymchak W, Noga M et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003; 108: 2066-9.Galie N, Ghofrani HA, Torbicki A et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353 (20): 2148-57.Galie N, Ghofrani HA, Torbicki A et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353 (20): 2148-57.Rubin LJ, Fleming T, Galiè N et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension. CHEST 2011; 140 (5): 1274-83.Rubin LJ, Fleming T, Galiè N et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension. CHEST 2011; 140 (5): 1274-83.Simonneau G, Rubin LJ, Galie N et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2006; 150 (1): 63.Simonneau G, Rubin LJ, Galie N et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2006; 150 (1): 63.
The authors declare that there are no conflicts of interest present.